EXHIBIT 10.26
000 Xxxxx Xxxx Tel: x0 000 000-0000
Ottawa, Ontario Fax: x0 000 000-0000
K2K 1X8 Canada
xxx.xxxxxxxxxx.xxx
(MDS NORDION LOGO)
November 21, 2006
Xxxxx Xxxxxx-Coco
Director, R&D Operations
Molecular Insight Pharmaceuticals, Inc.
000 Xxxxxx Xxxxxx
Xxxxxxxxx, XX 00000
Dear Xxxxx,
RE: AMENDMENT #3 TO AGREEMENT BETWEEN MDS NORDION, A DIVISION OF MDS (CANADA)
INC. ("MDS NORDION") AND MOLECULAR INSIGHT PHARMACEUTICALS, INC. (MIP) DATED
JUNE 14, 2004 (THE "AGREEMENT").
Reference is made to the Agreement between MDS Nordion and MIP dated the 14th
day of June, 2004 (the "Agreement").
In consideration of $1.00 and other valuable consideration the sufficiency of
which is hereby acknowledged, the parties desire to further amend the Agreement
and extend the term.
1. Section 16.1: Initial Term shall be amended to read as follows:
"The term of this agreement shall commence upon the Effective Date and,
unless terminated earlier pursuant to this agreement, or extended upon
mutual agreement of the parties, shall expire on December 31, 2007."
All other Terms and Conditions in this agreement shall remain in full force and
effect.
The foregoing amendment and agreement shall be effective as of the 26th day of
Nov., 2006.
In you agree with the foregoing, please execute this Agreement in the space
provided below.
-1-
[MDS Nordion LOGO]
MDS NORDION, A DIVISION OF MDS (CANADA) INC.
Per: /s/ Xxxxx Xxxxxx
Name: Xxxxx Xxxxxx
Title: Senior Vice President
Sales & Marketing
We agree this 26th day of November, 2006
MOLECULAR INSIGHT PHARMACEUTICALS INC.
Per: /s/ Xxxx X. XxXxxx
Name: Xxxx X. XxXxxx
Title: Chief Operating Officer
-2-
